Description
The Highly Galactosylated Anti-PD-L1 (Atezolizumab), a biobetter antibody contains with a high level of galactosylation.
Antibody Indication
Bladder cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced PD-L1 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD274
Full Name
CD274 molecule
Background
This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and nonhematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin Vlike and Clike domains. Interaction of this ligand with its receptor inhibits Tcell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic Tcell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants.
Alternative Names
B7-H, B7H1, PDL1, PD-L1, PDCD1L1, PDCD1LG1
Gene ID
29126
Cellular Localization
Plasma membrane, Endosome
Genecards
17635
Involvement in Disease
Its related pathways are Innate Immune System and Class I MHC mediated antigen processing and presentation.
Related Pathways
1.It plays a key role in inducing and maintaining immune tolerance to oneself (PubMed:11015443, PubMed:28813417, PubMed:28813410). As a ligand for the inhibitory receptor PDCD1/PD-1, it regulates the activation threshold of t cells and limits the effector response of t cells (PubMed:11015443, PubMed:28813417, PubMed:28813410). Through an unknown activation receptor, it is possible to stimulate a subset of T cells to mainly produce interleukin 10 (IL10) (PubMed: 10581077). 2. Tumors use the pdcd1 mediated inhibitory pathway to weaken anti-tumor immunity and escape the destruction of the immune system, thereby promoting tumor survival (PubMed:28813417, PubMed:28813410). The interaction with PDCD1/PD-1 inhibits the effector function of cytotoxic T lymphocytes (CTLs) (similar). The blockade of the pdcd1 mediated pathway leads to the reversal of the exhausted T cell phenotype and the normalization of the anti-tumor response, which provides a theoretical basis for cancer immunotherapy (through similarity).
Field of research
1.Ubiquitinated; STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation. 2.Glycosylation at Asn35, Asn192, Asn200, and Asn219 3.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
Atezolizumab
Description
Atezolizumab is a humanized monoclonal antibody that specifically targets cell death ligand 1 (PD-L1) programmed for proteins expressed on the surface of tumors. Atezolizumab was used to prevent the interaction of PD-L1 and PD-1 and eliminate the inhibitory effect on the immune response seen in some cancers.
Antibody Indication
Lung Cancer Small Cell Lung Cancer (SCLC)
Metastatic Non-Small Cell Lung Cancer
Triple Negative Breast Cancer (TNBC)
Urothelial carcinoma ureter metastatic
Locally advanced Urothelial Carcinoma
Lung Cancer Small Cell Lung Cancer (SCLC)
Metastatic Non-Small Cell Lung Cancer
Triple Negative Breast Cancer (TNBC)
Urothelial carcinoma ureter metastatic
Locally advanced Urothelial Carcinoma
